Peritoneal washing cytology at second-look laparotomy in cisplatin-treated ovarian cancer patients.
The use of peritoneal washing cytology during second-look laparotomy in 58 cisplatin-treated ovarian cancer patients was evaluated. Washing was performed for the 41 patients who showed no gross evidence of persistent disease. Peritoneal washing cytology was positive in 8 of 18 cases with histologically identified residual disease and in 4 of 23 cases without residual disease. However, three of the four cytologically positive patients without other evidence of disease later died of recurrences. The five-year survival rate of the 23 patients who showed no residual carcinomas macroscopically was 60.9%; when their washing cytologies were negative, there was a 73.7% five-year survival rate. These findings indicate that, despite its limitations, a peritoneal washing cytology at the time of second-look laparotomy is important to assess the response to treatment and to evaluate the prognosis of patients with ovarian cancer.
Kudo
R
R
Department of Obstetrics and Gynecology, Sapporo Medical College, Hokkaido, Japan.
Takashina
T
T
Ito
E
E
Mizuuchi
H
H
Sagae
S
S
Moriwaka
O
O
Tamagawa
A
A
D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007813:Laparotomy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology*; D010533:Peritoneal Lavage / Q000379:methods*
D002945:Cisplatin